AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval

Simply Wall St.10-02 02:21

AbbVie’s AbbVie stock has had a strong multiyear run, and with the price recently closing at US$261.59, the key issue is whether that level is backed by the cash the business is expected to generate. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2672480761?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/141885706-card/1789002767761","is_english":true,"pubTime":"2026-10-02 02:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672480761","market":"nz","top_or_hot":-1,"title":"AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval","media":"Simply Wall St.","content":"<div>\n<p>AbbVie’s AbbVie stock has had a strong multiyear run, and with the price recently closing at US$261.59, the key issue is whether that level is backed by the cash the business is expected to generate. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-41-undervalued-on-fda-approval\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-02 02:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-41-undervalued-on-fda-approval><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie’s AbbVie stock has had a strong multiyear run, and with the price recently closing at US$261.59, the key issue is whether that level is backed by the cash the business is expected to generate. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-41-undervalued-on-fda-approval\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1244550221.USD","symbol_name":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-41-undervalued-on-fda-approval","article_id":"2672480761","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/141885706-card/1789002767761"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-41-undervalued-on-fda-approval","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2672480761","pubTimestamp":1790878886,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AbbVie’s AbbVie stock has had a strong multiyear run, and with the price recently closing at US$261.59, the key issue is whether that level is backed by the cash the business is expected to generate. Recent drug approvals, partnerships and data readouts all feed into those future cash flows, which is where the valuation debate now sits.\n\nOver the past 5 years AbbVie has delivered a total return of 187.5%, which puts real weight on the question of whether the current share price is fully...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IXJ":"全球医疗业ETF-iShares","BK4533":"AQR资本管理(全球第二大对冲基金)","VHT":"Vanguard Health Care ETF","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","RXL":"ProShares Ultra Health Care","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","TRUH":"VanEck Healthcare TruSector ETF","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","SPHQ":"Invesco S&P 500 Quality ETF","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","ABBV":"艾伯维公司","IYH":"iShares U.S. Healthcare ETF","XLV":"健康照护类股ETF-SPDR","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","AGNG":"Global X Aging Population ETF","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4588":"碎股","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","PPH":"VanEck Pharmaceutical ETF","LABU":"三倍做多标普生物-Direxion","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","PJP":"INVESCO PHARMACEUTICALS ETF","FHLC":"Fidelity MSCI Health Care Index","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4581":"高盛持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4139":"生物科技"},"translate_title":"FDA 批准后，艾伯维 (ABBV) 股票可能被低估 41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PJP":0.6,"IYH":0.6,"DCF":1,"ABBV":1.5,"FTXH":0.6,"MEDX":0.6,"TRUH":0.6,"PPH":0.6,"LABU":1.5,"AGNG":0.6,"XLV":0.6,"FHLC":0.6,"IXJ":0.6,"VHT":0.6,"JDOC":0.6,"SPHQ":0.83,"GLAM":0.6,"RXL":0.6},"content_text":"AbbVie’s AbbVie stock has had a strong multiyear run, and with the price recently closing at US$261.59, the key issue is whether that level is backed by the cash the business is expected to generate. Recent drug approvals, partnerships and data readouts all feed into those future cash flows, which is where the valuation debate now sits.  Over the past 5 years AbbVie has delivered a total return of 187.5%, which puts real weight on the question of whether the current share price is fully supported by its underlying cash streams. The recent U.S. FDA approval of JUVMO for Parkinson’s disease, together with pipeline and AI driven R&D partnerships, can influence how investors think about the timing, durability and risk profile of AbbVie’s future cash flows. Prefer to judge AbbVie on earnings? See why AbbVie's 73.7x P/E tells a different valuation story.  The issue now is whether AbbVie’s current valuation can be explained by its cash flows when viewed through a Discounted Cash Flow (DCF) lens. If you want useful context around AbbVie and its cash flow story, compare it with companies filtered through 31 high quality undervalued stocks. AdvertisementIs AbbVie a Bargain on Cash Flow? The Discounted Cash Flow (DCF) approach here values AbbVie based on the cash it is forecast to return to shareholders. Over the last twelve months the group produced roughly $18.35b of free cash flow. The model then assumes this cash generation grows rather than shrinks over time, with projected free cash flows in the coming decade remaining in the tens of billions of dollars each year. Those cash projections, when discounted back, point to an estimated intrinsic value that the DCF suggests is substantially above the current share price of $261.59. The recent U.S. FDA approval of JUVMO for Parkinson’s disease is cited as support for the view that AbbVie’s late stage pipeline may help sustain those future cash flows, even though the exact contribution is still uncertain. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate. The AbbVie Narrative: What Would Justify Today's Price? Simply Wall St Narratives pick up where the AbbVie DCF puzzle leaves off by explaining which paths for growth, margins and earnings would need to hold for the shares to be worth materially more or less than today’s price. Each narrative links a specific fair value to a clear storyline about AbbVie’s potential catalysts and key risks, so you can track over time which version of events appears to be unfolding on the Community page. One of the top community narratives on AbbVie: 6% undervalued \"The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products…\" Discover why this Narrative puts AbbVie at 6% undervalued. AbbVie’s price is only one piece of the decision Before building an investment case around AbbVie, it helps to know that our broader checks have highlighted issues that could matter just as much as any cash flow model. Take a closer look at 4 warning signs before settling on a valuation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2672480761","isCrawlerRequest":true}